Impact of SGLT2 inhibitors on cardiovascular disease

Czech version

Authors: Hana Rosolová
Authors‘ workplace: Centrum preventivní kardiologie, II. interní klinika LF UK a FN Plzeň-Bory
Published in: AtheroRev 2022; 7(2): 82-84
Category: Reviews

Overview

Sodium-glucose transporter 2 inhibitors (SGLT2i) or gliflozines are new antidiabetic drugs, which have lots of non-glucose effects; those effects are influential in the reduction of fatal and non-fatal atherosclerotic cardiovascular disease, of hospitalization for heart failure and of all-cause death. The recent metaanalysis of ten prospective randomized clinical studies with SGLT2i and CVD – REAL data from 10 million patients with type 2 diabetes are presented. Gliflozines belong to the basic drugs for the prevention and treatment of heart failure with reduced ejection fraction in patients with and also without diabetes. Nephroprotective effects of gliflozines could include them among the drugs for patients with chronic renal diseases. Glilflozines exceed diabetology and become important drugs for cardiologists, nephrologists and internists too.

Keywords:

cardiorenal syndrome – type 2 diabetes mellitus – heart failure – inhibitors SGLT2 – atherosclerotic cardiovascular disease

Sources

1. Perkovic V, Jardine MJ, Neal B et al. [CREDENCE Trial Investigators]. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. NEJM 2019; 380(24): 2295–2306. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1811744>.

2. Bhatt DL, Szarek M, Pitt B et al. [SCORED Investigators]. Sotagliflozin in patients with diabetes and chronic kidney disease. NEJM 2021; 384(2): 129–139. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2030186>.

3. Neal B, Perkovic V, Mahaffey KW et al. [CANVAS Program Collaborative Group]. Canagliflozin and cardiovascular and renal events in type ě diabetes. NEJM 2017; 377(7): 644–657. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1611925>.

4. Zinnan B, Wannwe C, Lachin JM et al. [EMPA-REG OUTCOME Investigators]. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. NEJM 2015; 373(22): 2117–2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1504720>.

5. Wiviott SD, Raz I, Bonaca MP et al. [DECLARE-TIMIO 58 Investigators]. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. NEJM 2019; 380(4): 347–357. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1812389>.

6. Cannon CP, Pratley R, Dagogo-Jack S et al. [VERTIS CV Investigators]. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. NEJM 2020; 383(15): 1425–1435. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2004967>.

7. Bhatt DL, Szarek M, Steg PG et al. [SOLOIST-WHF Trial Investigators]. Sotagliflozin in patients with diabetes and recent worsening heart failure. NEJM 2021; 384(2): 117–128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2030183>.

8. McMurray JJ, Solomon SD, Inzucchi SE et al. [DAPA-HF Trial Cmmittees and Investigators]. Dapagliflozin in patients with heart failure and reduced ejection fraction. NEJM 2019; 38(21): 1995–2008. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1911303>.

9. Heerspink HJL, Stefansson BV, Correa-Rotter R et al. [DAPA-CKD Trial Committees and Investigators]. Dapagliflozin in patients with chronic kidney disease. NEJM 2020; 383(15): 1436–1446. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2024816>.

10. Packer M, Anker SD, Butler J et al. [EMPEROR-Reduced Trial Investigators]. Cardiovascular and renal outcomes with empagliflozin in heart failure. NEJM 2020; 383(15): 1413–1424. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2022190>.

11. Bhattarai M, Salih M, Regmi M et al. Association of Sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in patients with type 2 diabetes and other risk factors for cardiovascular disease. A meta-analysis.JAMA Network Open 2022; 5(1): e2142078. Dostupné z DOI: <http://dx.doi.org/10.1001/jamanetworkopen.2021.42078>.

12. Anker SD, Butler J, Filipatos JP et al. Empagliflozin and cardiovascular outcomes in heart failure with a preserved ejection fraction. NEJM 2021; 385(16): 1451–1461. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2107038>.

13. Khunti K, Kosiborod M, Kim DJ et al. Cardiovascular outcomes with sodium-glucose contransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. Cardiovascular Diabetol 2021; 20(1): 159. Dostupné z DOI: <http://dx.doi.org/10.1186/s12933–021–01345-z>.

14. Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors. JACC Basic Transl Sci 2020; 5(6): 632–644. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacbts.2020.02.004>.

15. American Diabetes Association. Standards of Medical Care in Diabetes – 2022. Diabetes Care 2021; 45(Suppl1). Dostupné z WWW: <https://diabetesjournals.org/care/issue/45/Supplement_1>.